The pharma's Discovery IT platform is freely available.

By Kevin Davies

July 14, 2008 | In an unusual move for big pharma, Eli Lilly has made its Discovery IT platform—known internally as the Lilly Science Grid (LSG)—open source. The initiative could spark new interest within the biopharma community for sharing pre-competitive content and software.

“This is something that John Reynders was interested in and has been in the works for a while,” says Susie Stephens, principal research scientist with Lilly. (Reynders left Lilly for Johnson & Johnson last year; see Reynders Takes the CIO Reins at J&J R&D, Bio-IT World, January 2008). The move addresses a key question: “Do [biopharma] all really need to manage very similar resources or are there areas where we can work together?”

LSG, which began in 2005, has a core framework to enable users to build plug-ins to create applications. “This is our core discovery IT framework, and was developed on the biology side, but has extended into chemistry internally,” explains Stephens. The current lead technologist is Andy Ring.

The software is available on Sourceforge.net. “It’s all well and good developing plug-ins internally for the framework, but if there are many people within the broader life sciences community doing that, it could make it much more interesting,” she says.

The publicly available version of LSG — dubbed Life Sciences Grid—includes a select group of “less proprietary” plug-ins, including those for Gene Browser, NCBI Entrez, and Gene Ontology. “We’re also kick-starting some collaborations, working with people in academia to develop plug-ins,” says Stephens. Indeed, she says at times Lilly’s open source ambitions are exceeding those of some potential academic partners. “We’d like to see many people building plug-ins, some of which we wouldn’t have thought to have done.”

But why go to the trouble? Says Stephens: “We’re looking to become much more networked as a company, so we’re looking hard at what we consider proprietary and what we must keep to ourselves, and what are we actually doing that other pharma companies are also doing that we consider to be pre-competitive.

“We don’t think it makes financial sense for all pharma and biotech companies to all be developing a core discovery IT framework... I’m not aware of a huge number of projects where pharma is making code available open source,” adds Stephens. She cites PISTOIA—a new initiative to share data models, and web-service interfaces in areas such as cheminformatics, which is also available through Sourceforge.

Stephens, who formerly was something of a Semantic Web guru at Oracle, is enjoying her matchmaking role at Lilly. She focuses chiefly on open innovation, identifying areas “where it makes sense for Lilly to establish external collaborations” and gaps in the company’s in-house capabilities or resources where it would make sense to find collaborators, in areas such as informatics and the Semantic Web. Another goal is to open a small “open innovation center,” probably in Cambridge, Mass., spun off from Lilly that would focus on pre-competitive collaborations across pharma, again in areas such as software and discovery IT.

LSG can be found at www.sourceforge.net (search “LSG”), under a Berkeley Software Development license.  

___________________________________________________

This article appeared in Bio-IT World Magazine.

Subscriptions are free for qualifying individuals.  Apply Today.